Hospitals face paying £8,000 a shift to cover striking doctors
Advice on the British Medical Association (BMA) website says consultants asked to cover shifts overnight in a hospital should have a second consultant on call with them to cover higher-level duties.
According to the BMA's rate card, for each junior doctor's overnight shift during the strike, two consultants in London would cover it for £334 per hour, or £4,008 for an overnight shift, totalling £8,016 for both consultants.
Hospital leaders described it as 'worrying' and said the funds needed to cover a striking doctor were 'unacceptable'.
One junior doctor, who is not striking in this round of industrial action but did last year, said some consultants were 'slower' at day-to-day activities on the ward, which sometimes led to multiple consultants covering one overnight shift.
'The type of things that you are doing overnight [are] quite different to the job that you do as a consultant during the day [but] something that the junior, the resident doctors, core and foundation trainees do all the time. Some of these might be quite practical and logistical things that if you're a consultant [you are] not physically used to doing on the computer system. They're the kind of things you need to do quickly overnight,' the doctor said.
While consultants could very ably clinically assess patients, they might be 'a bit slow' at the tasks needed overnight, the doctor suggested. 'Sometimes they feel safer, I think … having more of them on because, more from a speed perspective,' the doctor added.
• How much do NHS doctors really earn? Here are the facts
BMA guidance says some consultants may have 'concerns' about working on wards. ''Acting down' to provide cover for absent resident doctor colleagues may involve tasks that you have not had to perform for many years, and you may have concerns about the ability to carry out certain tasks involved in ward work,' the advice states.
'A consultant has a professional obligation to act within their sphere of competence. As such, you need to be clear with your employer that you do not feel that you can safely and competently perform the work required and that doing [so] may expose you to enhanced risk of medico-legal consequences. If your employer refuses to take the necessary action to make alternative arrangements […] then, as above, you will need to follow our guidance on raising concerns.'
One hospital executive said that while the hospital had not used more than one consultant to cover shifts, the cost of cover ran 'into the millions' and further cuts to NHS services might be needed as a result.
'The cost of consultant cover during the period, which runs into millions of pounds, [is a] huge amount of money that is unfunded. It's well publicised that there's a real tension at the moment in the NHS between safe timely services and financial viability,' said the executive, who did not wish to be named.
• Striking doctor called off picket line to treat 'very sick' babies
'We're trying to navigate our way along that. Inevitably, if we accumulate debt as a result of paying consultants more to pick up these shifts, that money is not going to be funded by our NHS. So it would be down for each individual NHS organisation to make further cuts to offset the cost of the strikes.'
Saffron Cordery, the deputy chief executive of NHS Providers, said: 'Trust leaders are working to minimise the harm and disruption caused by the strike. Ensuring adequate cover to keep patients safe is expensive and there is no extra money to cover this so the unexpected cost is bound to impact on the services they can provide.
'It's really worrying to see the demands for excessive rates to provide this cover. The withdrawal of labour by one staff group should not be seen as a financial opportunity for another. That is totally unacceptable.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
14 minutes ago
- The Independent
Can airdrops solve the Gaza crisis? Aid agencies are sceptical
The UK is set to join Jordan and the United Arab Emirates in airdropping aid into Gaza as starvation and malnutrition have reached perilous levels in the war-torn strip. Following pressure from the international community, Israel has announced brief 'humanitarian pauses' between 10am and 8pm each day to allow more aid to be delivered to starving Palestinians, as US president Donald Trump said on Monday: 'They have to get food and safety right now.' The World Health Organisation has warned that malnutrition is on a 'dangerous trajectory' in the Gaza Strip, with 63 deaths in July. Around one in five small children in Gaza City are now acutely malnourished, according to the UN's Palestinian refugee agency (UNRWA). Airdropping is a controversial method of aid distribution, as humanitarian organisations have cited a number of safety and efficiency issues. Médecins Sans Frontières (MSF) operations manager Jacob Burns called it 'humanitarian theatre', adding 'it's absolutely not the only way' to get aid into Gaza. 'For the International Committee of the Red Cross (ICRC), airdrops really are a last resort,' spokesperson Sarah Davies told The Independent, as the method comes with its own set of challenges. Here's all you need to know about the controversial aid distribution method. What is airdropping? Airdropping is usually reserved for instances when it is hard to get aid to where it needs to go. It involves dropping food or non-food items into an area from an aeroplane. Usually they require a predetermined location, with staff on the ground who have cleared the area of other people, buildings, or anything that could be damaged or damage the goods themselves. The aid then needs to be distributed on the ground. 'The most efficient way to do this is through things like international organisations who are experienced in this,' said Ms Davies. She added that the ICRC was not currently involved in the airdrops. 'We can't deliver assistance in a way that risks people or exposing them to harm. We work by assessing the needs throughout the areas of Gaza, where we're present, and we respond directly to those needs.' The dangers of airdropping In the densely populated Gaza Strip, airdropping faces a new challenge of distributing aid without causing harm to individuals. 'The primary danger of the airdrop is you cannot safely aim a pallet of aid,' said Mr Burns. 'People have already been killed by aid drops in Gaza.' Five people died in March last year after at least one parachute failed to deploy in an aid package airdrop, causing the parcel to fall on people, according to Gaza's health ministry. As well as the spatial safety issues, the sheer desperation of citizens can put their lives at risk as they race to get to the food source first. 'If you're starving and suddenly you see food drop out of the sky, obviously you're going to run towards that aid and it's a situation where the strongest will win,' said Mr Burns. He added that separate to Israel's claims that Hamas has been stealing aid, criminal gangs have used violence to loot aid – and airdropping offers no further control over that problem. 'If you're just throwing aid randomly into the Gaza Strip, then you have no idea who can control that.' How effectively does it distribute food? According to the ICRC, airdrops are a less efficient form of transporting aid than land transportation. 'They're really quite unsustainable, because they are very expensive', said Ms Davies, who explained that aeroplanes require fuelling and mechanical requirements that can make it a more expensive operation to supply 'quite limited amounts of items in a way that, unfortunately, we see doesn't always reach those who really need it'. Mr Burns added that airdrops don't allow for as much aid to get in as land transportation would, as he called on Israel to 'let aid in in a flood rather than a trickle, which is what airdrops are'. The ideal way of distributing aid The MSF worker then called for 'organised massive distributions of aid that can meet everyone's needs'. Land transportation, in which aid is brought into Gaza via trucks by humanitarian organisations, was named by the ICRC as a more effective approach to aid distribution because aid workers can bring in more supplies in a less time-consuming, resource-intensive way. The World Food Programme has said it has enough food to feed the entire population of 2.1 million people for almost three months. 'While we do welcome any decisions, any changes that mean that more aid reaches more people, we do reiterate that it needs to be done in a way where people are given dignified access to aid,' said Ms Davies. 'Doing aid entry and aid distribution from land transportation allows international organisations who have experience of decades of work in Gaza, who have the trust of the communities in Gaza, to do so in this way.'
Daily Mail
15 minutes ago
- Daily Mail
I lost my vision and became mute after developing a 'trifecta' of brain disorders
A Hawaiian woman who experienced a cascade of medical problems, including blindness and muteness was unknowingly suffering from a trifecta of neurological conditions at once. The 37-year-old woman appeared at a Honolulu emergency room after suddenly losing vision in her right eye. She had a history of Myasthenia Gravis (MG), an autoimmune disorder affecting the brain that causes intermittent muscle weakness in the neck, face, and limbs, but vision loss isn't typically common with the condition. Doctors later discovered that the optic nerve connecting her eyes to the brain was inflamed and the protective barriers around nerve cells in the spinal cord were breaking down. They diagnosed her with a second neurological autoimmune disorder, neuromyelitis optica (NMO). Two years later, she became depressed and unresponsive. She stopped speaking and seemed to ignore or not hear her doctors' commands. Comprehensive testing revealed she was suffering from a third autoimmune condition, anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, that caused brain inflammation and disrupted normal signaling, leading to new psychological problems. Doctors rarely see patients with overlapping neurological autoimmune disorders, according to NIH-funded research. Because many of them share similar symptoms, doctors are prone to missing a diagnosis or attributing it to one the patient has already received from another provider. These conditions are already rare on their own. MG affects around 20 out of every 100,000 people worldwide. While NMO afflicts around one in 100,000 and there are just about one to two cases of NMDAR per million people per year. The Hawaiian doctors said their case highlights the need for providers to consider the possibility that their patients are contending with chronic, harder-to-diagnose neurological conditions. The patient was diagnosed with MG 10 years earlier, leading to frequent debilitating muscle weakness. In cases of MG, the body's own cells attack healthy receptors located where nerves meet muscles, triggering a cascade of processes that facilitate muscle contraction. From walking to chewing, MG can affect any muscle system. Up to 20 percent of patients' lung muscles will weaken to the extent that they have trouble breathing on their own and require a ventilator. Losing vision in one eye, though, is not a typical symptom. When doctors investigated, not only was the optic nerve enlarged and inflamed, but scans of the woman's spine revealed that the myelin sheaths protecting nerve fibers were degrading. They detected antibodies commonly found in cases of NMO, which attack proteins in astrocytes – cells that protect brain cells. Attacks on proteins in astrocytes can enable inflammatory cells to enter the central nervous system, exacerbate brain inflammation, and initiate the breakdown of the blood-brain barrier. Over the long term, this can lead to vision loss, chronic brain inflammation, paralysis, and permanent brain damage. Two years later, the doctor reported the woman came to the hospital again with 'significant behavioral changes, including neglecting her usual activities and displaying diminished responsiveness.' 'She became mute and uncooperative with commands,' doctors added. Doctors suspected they were dealing with a case of anti-NMDAR encephalitis, a condition in which the body's immune cells attack NMDA receptors in the brain, which act like a switch for strengthening or weakening brain connections that are crucial for memory and learning. NMDA receptors also regulate brain signaling, helping brain cells communicate with one another. Low levels of receptor activity has been linked to schizophrenia, causing psychosis and hallucinations, depression, bipolar disorder, and anxiety. Doctors conducted comprehensive lab tests, imaging, assessments and a test of her cerebral spinal fluid, which confirmed the third neurological autoimmune diagnosis. 'This case underscores the critical need for clinicians to remain alert to overlapping neurological conditions, enabling timely diagnoses and interventions that can help improve clinical outcomes and prevent unnecessary delays in treatment,' doctors wrote in the American Journal of Case Reports. The combination of three autoimmune disorders is called multiple autoimmune syndrome. One of these disorders typically affects the skin, usually in the form of vitiligo or alopecia. But a single patient having the disorders that the Hawaiian woman has is far less common than co-occurring general autoimmune conditions, like rheumatoid arthritis or Hashimoto's thyroiditis. About 25 percent of people with one autoimmune disease develop another, and patients are more often female. They each target distinct cells within the body and have differing underlying triggers. NMDAR, for example, is often the result of a tumor producing NMDA receptors, and the immune system attacks those made by the tumor, as well as those in the healthy brain. Doctors did not report whether their patient had a history of cancer, though. NMO, meanwhile, is not linked to cancer, and antibodies target proteins in astrocytes, which are found in the optic nerves and spinal cord. The woman was treated with a plasma exchange treatment, which filters out harmful antibodies from the blood. Once doctors did this, her brain swelling and function improved.
Telegraph
15 minutes ago
- Telegraph
New drug could halt Alzheimer's
A new drug could halt the progression of Alzheimer's disease. Trials suggest the treatment, called trontinemab, could be the most powerful weapon yet against dementia. Research will now examine whether the drug should be given to those without any symptoms in order to prevent the disease. Results presented at the Alzheimer's Association International Conference in Toronto found the 'game-changing' treatment can clear the devastating plaques associated with Alzheimer's far more rapidly than any current licensed drug. Nine in 10 patients prescribed trontinemab experienced amyloid clearance within 28 weeks, meaning visible markers of disease had vanished. Experts hope these changes will be matched by improvements in memory and functioning, with an 18-month trial of 1,600 patients now under way. Separate research will examine whether the drug could be given to people without any signs of dementia, in the same way that statins are used to ward off heart disease. On Monday, experts said the findings were 'very promising', suggesting that the drug was much more powerful than existing medications, with far fewer side effects. Around one million people in the UK suffer from dementia, with Alzheimer's disease the most common form. Powerful precise effects at low doses Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials suggest that, in less than seven months, it has outperformed the ability of existing drugs to clear plaques in 18 months. Experts hope that if given early enough, the drug could save some patients from developing symptoms at all. It has been engineered to more easily cross the blood-brain barrier, meaning it can ensure powerful precise effects at low doses. The lack of side effects means it could be offered to large populations. This also means it could be offered at a far lower price than current medications, which require intense monitoring, including regular scans. Experts believe it could become the first Alzheimer's drug to be funded by the NHS. Last year, medicines regulators in the UK gave the green light to the first two treatments found to slow progression of Alzheimer's disease. Both lecanemab and donanemab use monoclonal antibodies to clear amyloid plaques in Alzheimer's disease. In trials they have been found to slow decline by 27 per cent and 35 per cent respectively, over 18 months. However, the risk of brain swelling and brain bleeds means they need intense monitoring. The new drug appears to have a far better safety profile. The phase two trial of 149 patients found less than five per cent of cases suffering amyloid-related imaging abnormalities, and all cases quickly resolved. It also requires less frequent infusions, with mass trials to examine the impact of giving the drug to patients once a month for six months, then every three months. Scientists have been intrigued by the promise of trontinemab because of the way it has been designed to be transported across the blood brain-barrier, which normally prevents chemicals in the bloodstream from entering the brain. 'Game-changing' Prof Sir John Hardy,the chairman of molecular biology of neurological disease at University College London's Institute of Neurology said the advance could be 'game-changing'. He told The Telegraph: 'This is absolutely great news. It sucks the plaque out of the brain really quickly, much faster than we have seen with lecanemab or donanemab.' The scientist, who was the first to identify the role of amyloid in the disease, said the drug's safety profile was a 'massive improvement' on the current drugs on the market, raising hopes it could be used both to prevent disease and stop it in its tracks. He said: 'There is no doubt this could be game-changing. We hope that if we can use these drugs to people early, we can halt the progression of disease, even before people have symptoms. Now we need to see the size of the clinical effect.' Neither of the current drugs have been funded by the NHS as a result of their high costs, much of which stems from the need for intense monitoring, including regular scans. Prof Hardy said: 'These results show it is much faster and safer than previous drugs, which means less monitoring. That brings down the cost significantly, it means fewer MRI scans, so that would surely mean it would get Nice [National Institute of Health and Care Excellence] approval.' 'Very promising evidence' Prof Jonathan Schott, the chief medical officer at Alzheimer's Research UK said: 'We urgently need a range of treatments for Alzheimer's that are effective and safe for the people affected by this devastating disease. 'Evidence presented at the Alzheimer's Association conference in Toronto on trontinemab is very promising, showing that the drug can effectively and rapidly clear amyloid from the brain, seemingly with very few side effects. 'We now need to see whether these early stage results carry through to later stage clinical trials, which are planned to start later this year, including in the UK. These trials will show whether the drug is not only safe, but impacts on memory, thinking and quality of life.' He said it was 'exciting' that the drug would now be tested in some people without symptoms under the phase three trials. Levi Garraway, Roche's chief medical officer said: 'Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. 'With plans for phase three trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying – and ultimately preventing – progression of this devastating condition.'
